Compare US Global Jets ETF (JETS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Merck & Co., Inc. — how do they compare? US Global Jets ETF trades at $27.09 (market cap $878.48M), while Merck & Co., Inc. trades at $142.89 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 399.9× US Global Jets ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and Merck & Co., Inc. for 98 Days on average.
| JETS | MRK | |
|---|---|---|
Market Cap | $878.48M | $351.28B |
Volume | 4,465,925 | 7,969,665 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $156.43 |
52-Week Low | $23.64 | $82.49 |
Typical Hold Time | 26 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS (U.S. Global Jets ETF) trades at $27.67, down 1.53% with a bearish technical outlook. The ETF faces headwinds from rising fuel costs and geopolitical tensions impacting airline profitability. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, though RSI suggests potential oversold conditions. Recent news highlights competitive pressure from defense-focused aerospace ETFs that have outperformed JETS on total returns.
The outlook remains challenging with fuel cost volatility and competitive ETF alternatives presenting risks. However, oversold technical conditions and potential travel demand recovery offer selective opportunities for investors seeking airline exposure. Key catalysts include fuel price stabilization and holiday travel trends.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
